These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

872 related items for PubMed ID: 18268356

  • 1. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR.
    J Clin Oncol; 2008 Mar 10; 26(8):1331-7. PubMed ID: 18268356
    [Abstract] [Full Text] [Related]

  • 2. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR, Kauff ND, Domchek SM.
    J Natl Cancer Inst; 2009 Jan 21; 101(2):80-7. PubMed ID: 19141781
    [Abstract] [Full Text] [Related]

  • 3. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO.
    Cochrane Database Syst Rev; 2018 Aug 24; 8(8):CD012464. PubMed ID: 30141832
    [Abstract] [Full Text] [Related]

  • 4. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.
    N Engl J Med; 2002 May 23; 346(21):1609-15. PubMed ID: 12023992
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR.
    JAMA; 2010 Sep 01; 304(9):967-75. PubMed ID: 20810374
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, van der Vegt B, Greuter MJ, de Bock GH.
    Cancer Prev Res (Phila); 2012 Nov 01; 5(11):1291-7. PubMed ID: 23009828
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ, Lee SW, Kim KR, Jung KH, Lee JW, Kim YM.
    J Gynecol Oncol; 2017 Jan 01; 28(1):e3. PubMed ID: 27670257
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, Teule A, Brunet J, Y Cajal TR, Llort G, Dienstmann R, Rue M, Domchek SM, Balmaña J.
    Eur J Cancer; 2020 Jun 01; 132():53-60. PubMed ID: 32325420
    [Abstract] [Full Text] [Related]

  • 16. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
    Eur J Cancer; 2013 Jan 01; 49(1):132-41. PubMed ID: 22921157
    [Abstract] [Full Text] [Related]

  • 17. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Solsky I, Chen J, Rebbeck TR.
    Gynecol Oncol; 2020 Feb 01; 156(2):363-376. PubMed ID: 31918993
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
    Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND.
    JAMA Oncol; 2016 Nov 01; 2(11):1434-1440. PubMed ID: 27367496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.